Author: Nancy Stagliano

Nancy Stagliano, Ph.D. joined iPierian as Chief Executive Officer in September 2011 with an accomplished career as a biotech leader spanning all aspects of the industry, from discovery research and strategy to global medical affairs and corporate communications. Prior to joining iPierian, Dr. Stagliano was CEO of CytomX Therapeutics, a company where she was co-founder and a lead inventor on the patents for CytomX’s Probody platform. In earlier roles with CytomX, she served as the COO of CytomX LLC, which launched CytomX Therapeutics as well as Cynvenio Biosystems. Before moving to California, Nancy joined the Cambridge, Massachusetts, biotechnology industry in the late 1990s, where she had an eight-year tenure at Millennium Pharmaceuticals and consulted to several local startups. Dr. Stagliano received her BS in Electrical Engineering and her MS in Biomedical Engineering, both from Drexel University in Philadelphia. She obtained her PhD in Neuroscience from the University of Miami, followed by three years as an independently-funded research fellow at the Massachusetts General Hospital and Harvard Medical School, where she studied mechanisms of brain injury after stroke